A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 May 2018
At a glance
- Drugs SGN CD19B (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2016 Status changed from planning to recruiting, as reported, as reported by Seattle Genetics media release .
- 04 Nov 2015 New trial record